Introduction: Allo-HCT is considered a curative treatment for AML; however, leukemia relapse remains the major cause of mortality after HCT. Extramedullary relapse after HCT for AML is a rare event and its characteristics and prognosis are less well defined than systemic relapse. We studied 436 AML allo-HCT patients and analyzed the characteristics and outcomes of 128 patients who had post-HCT leukemia relapse; 25 with extramedullary relapse. Methods: We retrospectively studied all AML patients transplanted at the University of Minnesota (UM) between 1996 and 2008 who developed either a bone marrow or extramedullary relapse. Patient demographics, transplant-related variables and outcomes were prospectively collected and available from the UM transplant data base. Data regarding site of relapse, therapy and outcome postrelapse were collected from the patients' available medical records. Survival through 6 months post-relapse was estimated using Kaplan-Meier curves. Results: Of 128 patients who relapsed post HCT, 25 occured in extramedullary sites, either isolated (n 5 13, group I) or with concomittant marrow relapse (n 5 12, group BM). Relapse sites were bone (n 5 1), central nervous system (n 5 6), gastrointestinal (n 5 4), lymphatic (n 5 4), skin (n 5 5), genitourinary (n 5 1), pulmonary (n 5 1) and soft tissue (n 5 3). The median time to relapse was longer in the extramedullary sites than marrow only (328 vs 168 days). Patients with extramedullary relapse were more likely to have had preceding grade II-IV acute GVHD (77% vs 49%; p 5 0.03) or chronic GVHD (46% vs 15%; p 5 0.02) compared to marrow relapse only. Among all relapsed patients, chronic GVHD and relapse within 6 months of HCT were associated with worse overall survival. However, 6 month survival post relapse was significantly better for isolated extramedullary relapse (69%) compared to combined marrow and extramedullary (8%) or marrow relapse alone (27%) (p \ 0.01). In patients who had isolated extramedullary relapse, administration of systemic therapy (6 local to relapse site) yielded better 6 months OS (40-56%) than local (OS 33%) alone. Conclusion: This study suggests that there may be different pathogenesis for marrow versus extramedullary relapse of AML following allo-HCT. GVHD and accompanying GVL may better protect marrow sites, but patients with extramedullary relapse have better outcomes and have good responses to combined local and systemic therapy.
Introduction: Allo-HCT is considered a curative treatment for AML; however, leukemia relapse remains the major cause of mortality after HCT. Extramedullary relapse after HCT for AML is a rare event and its characteristics and prognosis are less well defined than systemic relapse. We studied 436 AML allo-HCT patients and analyzed the characteristics and outcomes of 128 patients who had post-HCT leukemia relapse; 25 with extramedullary relapse. Methods: We retrospectively studied all AML patients transplanted at the University of Minnesota (UM) between 1996 and 2008 who developed either a bone marrow or extramedullary relapse. Patient demographics, transplant-related variables and outcomes were prospectively collected and available from the UM transplant data base. Data regarding site of relapse, therapy and outcome postrelapse were collected from the patients' available medical records. Survival through 6 months post-relapse was estimated using Kaplan-Meier curves. Results: Of 128 patients who relapsed post HCT, 25 occured in extramedullary sites, either isolated (n 5 13, group I) or with concomittant marrow relapse (n 5 12, group BM). Relapse sites were bone (n 5 1), central nervous system (n 5 6), gastrointestinal (n 5 4), lymphatic (n 5 4), skin (n 5 5), genitourinary (n 5 1), pulmonary (n 5 1) and soft tissue (n 5 3). The median time to relapse was longer in the extramedullary sites than marrow only (328 vs 168 days). Patients with extramedullary relapse were more likely to have had preceding grade II-IV acute GVHD (77% vs 49%; p 5 0.03) or chronic GVHD (46% vs 15%; p 5 0.02) compared to marrow relapse only. Among all relapsed patients, chronic GVHD and relapse within 6 months of HCT were associated with worse overall survival. However, 6 month survival post relapse was significantly better for isolated extramedullary relapse (69%) compared to combined marrow and extramedullary (8%) or marrow relapse alone (27%) (p \ 0.01). In patients who had isolated extramedullary relapse, administration of systemic therapy (6 local to relapse site) yielded better 6 months OS (40-56%) than local (OS 33%) alone. Conclusion: This study suggests that there may be different pathogenesis for marrow versus extramedullary relapse of AML following allo-HCT. GVHD and accompanying GVL may better protect marrow sites, but patients with extramedullary relapse have better outcomes and have good responses to combined local and systemic therapy. Background: Current concepts of NK alloreactivity are based on donor/recipient KIR ligand mismatching and on donor KIR genotype variants, while little is known about the role of specific activating KIR genes. Specifically, the importance of the telomeric KIR2DS1 and KIR3DS1genes, and the centromeric KIR2DS2 gene has not been studied in detail. We tested the hypothesis that individual donor activating KIR genes would influence the outcome of AML patients undergoing unrelated allogeneic HCT. Methods: Donor KIR genotyping was performed for 1228 AML patients receiving transplants between 1989 and 2008 from 9/10 or 10/ 10 HLA-matched unrelated donors with outcome data provided by the CIBMTR. HLA genotyping was verified through the NMDP retrospective typing program. Cox regression was used to examine the association between donor KIR genotype and HCT outcome. Objectives: Donor T lymphocytes play a critical role in graft-versushost disease (GVHD) and infection prevention in allo-HSCT. CD28 is the primary T-cell costimulatory molecule constitutively expressed on T cells, which transduces a signal that enhances the activation and proliferation of T cells. Another member of the CD28 family is inducible co-stimulator (ICOS). Although not constitutively expressed, ICOS is rapidly upregulated on T cells upon activation. Cytotoxic Tlymphocyte antigen 4 (CTLA-4), a homologous molecule of CD28, is a key factor in regulating and maintaining self-tolerance, providing a negative signal to T cells. The aim of this study was to analyze donor and recipient T-cell costimulatory molecule gene polymorphisms associated with CMV infection within 100 days after HSCT. Methods: We analyzed 5 single nucleotide polymorphisms (SNPs): CD28 -594(A/G), ICOS -693(G/A) and CTLA-4 -1722(A/G), 149 (A/G) and CT60 (A/G) in a cohort of 116 pairs of recipients and unrelated donors and a second cohort of 87 pairs of recipients and HLA-identical sibling donors. Results: (1) All patients and donors are CMV seropositive before HSCT (only one donor from Taiwan is CMV seronegative). 117 patients (57.6%) had experienced early CMV infection with a median onset of 26 days (range2-64) after HSCT. 23% of 117 patients developed infection during granulocytopenia and 77% after neutrophil recovery. 92.3% of 117 patients developed CMV positive antigenemia without disease, only 9 patients developed CMV disease (7 patients with pneumonia and 2 patients with enteritis). (2) Patients receiving stem cells from a donor with CTLA-4 CT60 AA genotype had a higher incidence of early CMV infection than those with AG/ GG genotypes in both the unrelated and sibling cohorts. (3) Multivariate analysis identified four risk factors for early CMV infection: patients with CMV reactivation pre-HSCT (RR: 0.668, 95%CI: 0.454-0.983, P 5 0.041), unrelated donor (RR: 0.528, 95%CI: 0.349-0.8, P 5 0.003), patients experiencing aGVHD (RR: 1.606, 95%CI: 1.074-2.403, P 5 0.021) and donors with CTLA-4 CT60 AA genotype (RR: 2.369, 95%CI: 1.461-3.841, P \ 0.001). Conclusion: Although CMV disease has been reduced in the era of antiviral prophylaxis and preemptive therapy, our findings suggest the incidence of CMV infection remains high and provide the first report of relationship between T-cell costimulatory molecule gene polymorphic features to the risk of early CMV infection.
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